Avalo Therapeutics (NASDAQ:AVTX) Insider Paul Varki Sells 75,063 Shares

Avalo Therapeutics, Inc. (NASDAQ:AVTX) insider Paul Varki sold 75,063 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the sale, the insider owned 3,634 shares of the company’s stock, valued at approximately $73,297.78. The trade was a 95.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Avalo Therapeutics Stock Performance

Avalo Therapeutics stock opened at $22.87 on Friday. Avalo Therapeutics, Inc. has a 1 year low of $3.39 and a 1 year high of $24.27. The firm’s 50-day moving average is $15.61 and its 200-day moving average is $16.35. The company has a market cap of $610.86 million, a P/E ratio of -3.99 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.54) by $1.17. The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of ($0.21) million. As a group, sell-side analysts predict that Avalo Therapeutics, Inc. will post -3.38 earnings per share for the current year.

Wall Street Analyst Weigh In

AVTX has been the topic of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Wednesday, April 8th. Wall Street Zen upgraded Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. Citigroup reaffirmed an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday. Wedbush raised their target price on Avalo Therapeutics from $29.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Guggenheim assumed coverage on shares of Avalo Therapeutics in a report on Monday, February 2nd. They set a “buy” rating and a $50.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.14.

Key Avalo Therapeutics News

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: Positive Phase 2 LOTUS topline results announced for abdakibart (met primary HiSCR75 endpoint at Week 16 for both doses, benefits on key secondaries and a favorable safety profile); company plans to advance to registrational Phase 3 — this is the primary catalyst behind the rally as it materially derisks the program’s clinical path. QuiverQuant: LOTUS results & financing
• Positive Sentiment: Several firms raised ratings/targets after the data: BTIG ($58 PT), Citizens JMP (to $62), Wedbush (to $40) — analyst upgrades amplify buying interest and signal stronger Street conviction on upside if Phase 3 succeeds. BTIG price target raise
• Neutral Sentiment: Underwritten public offering priced to raise roughly $375M (19.73M shares + 1.4M pre?funded warrants at $17.75) to fund abdakibart Phase 3 and corporate purposes — materially increases cash runway (positive for program execution) but will change capitalization. Offering expected to close May 7, 2026. GlobeNewswire: $375M offering
• Negative Sentiment: Planned share sale implies near?term dilution for existing holders; depending on takeup and any exercise of underwriter’s option, EPS/ownership will be diluted and could cap upside until Phase 3 readouts. QuiverQuant: offering details & implications
• Negative Sentiment: Insider selling disclosed — Paul Varki sold 75,063 shares under a pre?arranged Rule 10b5?1 plan (filed with the SEC); large insider sales can be interpreted negatively by some investors despite 10b5?1 context. SEC Form 4: Varki sale
• Negative Sentiment: Unusually large put option activity was reported (heavy put purchases), which can signal hedging or speculative bets against the stock and may add volatility. Options flow report

Hedge Funds Weigh In On Avalo Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP acquired a new stake in Avalo Therapeutics in the 1st quarter valued at approximately $607,000. AlphaCentric Advisors LLC acquired a new position in Avalo Therapeutics during the 1st quarter worth $174,000. Seven Fleet Capital Management LP bought a new position in shares of Avalo Therapeutics in the fourth quarter worth $1,150,000. XTX Topco Ltd grew its stake in shares of Avalo Therapeutics by 190.0% in the fourth quarter. XTX Topco Ltd now owns 40,458 shares of the company’s stock worth $735,000 after purchasing an additional 26,508 shares in the last quarter. Finally, Squadron Capital Management LLC acquired a new position in shares of Avalo Therapeutics during the fourth quarter valued at $2,361,000. 87.06% of the stock is owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.